| [1] |
Handler S. Lung cancer and smoking[J]. CA Cancer J Clin,1991,41(6):371.
|
| [2] |
Lubin J H, Caporaso N, Wichmann H E, et al. Cigarette smoking and lung cancer: modeling effect modifi cation of total exposure and intensity[J]. Epidemiology,2007,18(5):639-48.
|
| [3] |
Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profi les--database and tools update[J]. Nucleic Acids Res,2007,35(Database issue):D760-5.
|
| [4] |
Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts[J]. Nucleic Acids Res,2005,33(Web Server issue):W741-8.
|
| [5] |
von Pawel J, Wagner H, Niederle N, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer[J]. Semin Oncol,1996,23(6 Suppl 16):47-50.
|
| [6] |
Dimitroulis J, Rapti A, Stathopoulos GP, et al. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study[J]. Oncol Rep,2008,20(4):879-84.
|
| [7] |
Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, et al. Insights into the mechanism of microtubule stabilization by Taxol[J]. Proc Natl Acad Sci U S A,2006,103(27):10166-73.
|
| [8] |
Ling X, Bernacki RJ, Brattain MG, et al. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest[J]. J Biol Chem,2004,279 (15) :15196-203.
|
| [9] |
Feun LG, Savaraj N, Solomon J, et al. Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer[J]. Am J Clin Oncol,1996,19(2):190-2.
|
| [10] |
Sculier JP, Ghisdal L, Berghmans T, et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature[J]. Br J Cancer,2001,84(9):1150-5.
|
| [11] |
Radhakrishnan A, Bitran JD, Milton DT, et al. Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial[J]. J Chemother,2009,21(4):439-44.
|
| [12] |
Park SH, Hong J, Kim YS, et al. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer[J]. Lung Cancer,2008,62(1):72-7.
|
| [13] |
Kretzschmar A, Drings P. Epirubicin weekly in combination chemotherapy with cyclophosphamide and vincristine in untreated small cell lung cancer: a phase II trial[J]. Onkologie,1990,13(2):141-2.
|
| [14] |
Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB[J]. Pharmacogenomics,2010,11(4):501-5.
|
| [15] |
Metcalfe SA, Cain K, Hill BT. Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines[J]. Cancer Lett,1986,31(2):163-9.
|
| [16] |
Perumal D, Singh S, Yoder S J, et al. A novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLC[J]. PLoS One,2012,7(8):e43589.
|
| [17] |
Kato T, Daigo Y, Aragaki M, et al. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients[J]. Lung Cancer, 20 11,74(1):124-31.
|
| [18] |
Lu B, Gonzalez A, Massion PP, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer[J]. Br J Cancer,2004,91(3):537-40.
|
| [19] |
Arivazhagan A, Kumar DM, Sagar V, et al. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor[J]. J Neurooncol,2012,107(2):289 -97.
|
| [20] |
Konecny GE, Pauletti G, Untch M, et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer[J]. Breast Cancer Res Treat,2010,120(2):481-9.
|
| [21] |
Nakano Y, Sumi T, Teramae M, et al. Expression of the mitotic-arrest defi ciency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma[J]. Oncol Rep,2012,28(4):1200-4.
|
下载:
